DABRA Laser to be Presented as a Frontline Therapy for CLI at the 2019 SCAI Scientific Sessions

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra
Medical Systems, Inc. (NYSE: RMED) today announced that Dr. Mohammad
Ansari will present DABRA as a treatment for critical limb
ischemia (CLI) during a scientific case review May 21 at the SCAI annual
meeting in Las Vegas.

“The unique DABRA catheter and laser system is a highly effective
frontline therapy for peripheral artery disease (PAD) that provides my
patients excellent results, shorter rehabilitation time, and shorter
hospitalizations,” said Dr. Ansari, Director of the Cardiac Cath Lab,
Structural Heart & Interventional Cardiology Research and Assistant
Professor, Division of Cardiology, at Texas Tech University Health
Sciences Center. “As demonstrated in this case, DABRA is a new,
effective technology for the revascularization of CLI and acute limb
ischemia where other devices could not rescue the limb.”

The presentation, titled, “Innovation Update: Redefining Excimer
Laser Photoablation – A Case Review Demonstrating the Utility and
Versatility of DABRA as a Front Line Therapy for CLI,” will take
place on Tuesday, May 21 at 3:50 pm in the Innovation Showcase
Theater. For more information about Dr. Ansari’s presentation at
SCAI, please visit Ra Medical Systems at Booth No. 408.

“Recent analysis suggests that 17.6 million people in the U.S. suffer
from PAD,” said Dean Irwin, CEO, Ra Medical Systems. “We at Ra Medical
are dedicated to providing a better solution for these patients.”

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation
Ablation) is a novel, minimally invasive excimer laser system that
non-thermally and photochemically ablates channels in vascular
blockages. The technology reduces all plaque types into their
fundamental chemistry, such as proteins, lipids and other chemical
compounds, eliminating blockages by dissolving them without generating
potentially harmful particulates. Unlike many mechanical, acoustic or
thermal treatments for PAD that may damage the arterial wall, DABRA
treats blockages with minimal vascular trauma.

SCAI (Society for Cardiovascular Angiography and Interventions) is
taking place in Las Vegas, NV, at The Cosmopolitan’s Innovation Showcase
Theater through May 22, 2019. Each year, the SCAI annual meeting
attracts 2,000 physicians, cardiovascular professionals, hospital
administrators, academics and industry professionals from around the
world to share knowledge, clinical expertise and the latest medical
advances, with the single goal of advancing care to save and enhance
lives.

About Ra Medical Systems

Ra Medical Systems is a commercial medical device company developing and
marketing innovative excimer laser systems for the treatment of vascular
and dermatologic diseases. DABRA launched in 2017 for the endovascular
treatment of blockages resulting from lower extremity vascular disease.
Pharos launched in 2004 for the treatment of dermatological disorders
including psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos
are based on Ra Medical’s core excimer laser technology platform that
produces 308 nanometer light, a UVB wavelength that studies have
demonstrated increases T-cell apoptosis, or cell death, which may
produce a beneficial, targeted immunosuppressive effect. Ra Medical
manufactures DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is licensed by
the state of California to manufacture sterile, single-use catheters in
controlled environments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events or Ra
Medical’s future financial or operating performance. In some cases, you
can identify forward-looking statements because they contain words such
as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,”
“intends,” “target,” “projects,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative of
these words or other similar terms or expressions that concern Ra
Medical’s future expectations, strategy, plans or intentions.
Forward-looking statements in this press release include, but are not
limited to, statements regarding the potential benefits to patients and
physicians using the DABRA catheter and laser system. Ra Medical’s
expectations and beliefs regarding these matters may not materialize,
and actual results in future periods are subject to risks and
uncertainties that could cause actual results to differ materially from
those projected or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated with
acceptance of DABRA and Pharos and procedures performed using such
devices by physicians, payors, and other third parties; development and
acceptance of new products or product enhancements; clinical and
statistical verification of the benefits achieved via the use of Ra
Medical’s products; the Company’s ability to effectually manage
inventory; Ra Medical’s ability to recruit and retain management and key
personnel; Ra Medical’s need to comply with complex and evolving laws
and regulations; intense and increasing competition and consolidation in
Ra Medical’s industry; the impact of rapid technological change; costs
and adverse results in any ongoing or future legal proceedings; adverse
outcome of regulatory inspections; and the other risks and uncertainties
described in Ra Medical’s news releases and filings with the Securities
and Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical’s business and
operating results is contained in Ra Medical’s quarterly report on Form
10-Q for the quarter ended March 31, 2019 and in its other filings with
the Securities and Exchange Commission. The forward-looking statements
in this press release are based on information available to Ra Medical
as of the date hereof, and Ra Medical disclaims any obligation to update
any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material
information to the public about the Company through a variety of means,
including our website (www.ramed.com),
our investor relations website (https://ir.ramed.com/),
press releases, SEC filings, and public conference calls in order to
achieve broad, non-exclusionary distribution of information to the
public and to comply with our disclosure obligations under Regulation
FD. We encourage our investors and others to monitor and review the
information we make public in these locations as such information could
be deemed to be material information. Please note that this list may be
updated from time to time.

Contacts

Media Contacts
Caitlin Kasunich / Lisa Lipson
KCSA
Strategic Communications
212.896.1241 / 508.843.6428
ckasunich@kcsa.com
/ llipson@kcsa.com

Investor Contact
Jeffrey Kraws
President, Ra Medical
Systems
760.707.7516
investorrelations@ramed.com